Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 143-155

  Reck, Martin ^a,b   Kaiser, Rolf ^c   Mellemgaard, Anders ^d   Douillard, Jean Yves ^e   Orlov, Sergey ^f   Krzakowski, Maciej ^g   von Pawel, Joachim ^h   Gottfried, Maya ⁱ   Bondarenko, Igor ^j   Liao, Meilin ^k   Gann, Claudia Nanette ^c   Barrueco, José ^l   Gaschler Markefski, Birgit ^c   Novello, Silvia ^m  

^a Lung Clinic Grosshansdorf   (Germany)

^b GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e René Gauducheau Center   (France)

^f PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h Pneumology Clinic   (Germany)

ⁱ MEIR MEDICAL CENTER   (Israel)

^j Dnipropetrovsk State Medical Academy   (Ukraine)

^k SHANGHAI JIAO TONG UNIVERSITY   (China)

^l BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^m UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; DOCETAXEL; NINTEDANIB; PLACEBO;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BLOOD TOXICITY; BRAIN METASTASIS; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RISK FACTORS; SOUTH AFRICA; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892967581     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70586-2     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2013, International Agency for Research on Cancer, Lyon.
2. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Nal Compr Canc Netw 2012, 10:1236-1271.
3. Leighl NB Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 2012, 19:S52-S58.
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
6. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
7. Mross K, Stefanic M, Gmehling D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clinical Cancer Res 2010, 16:311-319.
8. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011, 22:1374-1381.
9. Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011, 105:1640-1645.
10. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clinical Cancer Res 2010, 16:2881-2889.
11. Hanna NH, Kaiser R, Sullivan RN, et al. LUME-Lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer after failure of first-line chemotherapy. Proc Am Soc Clin Oncol 2013, abstr 8034.
12. Hanna NH, Kaiser R, Joo-Hang K, et al. Retrospective evaluation of the futility analysis in LUME-Lung 2, a randomised, double-blind, placebo-controlled phase III trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first-line chemotherapy. Eur J Cancer 2013, 49:3418. (abstr).
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United StatesNational Cancer Institute of the United States, National Cancer Institute of CanadaNational Cancer Institute of Canada.
14. Lan K, DeMets D Discrete sequential boundaries for clinical trials. Biometrika 1983, 70:659-663.
15. Kaiser R, Barrueco JR, Reck M, et al. Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials. Eur J Cancer 2013, 49:3479. (abstr).
16. Schemper M, Smith TL A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
17. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009, 86:167-174.
18. Reck M, Novello S, Mellemgaard A, et al. Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: a randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy. J Thorac Oncol 2013, 8:O16.01. (abstr).
19. Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11:619-626.
20. Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012, 30:3640-3647.
21. Herbst RS, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011, 377:1846-1854.
22. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012, 30:2070-2078.
23. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
24. de Boer RH, Arrieta O, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29:1067-1074.
25. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30:3084-3092.
26. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
27. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010, 28:49-55.
28. Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012, 30:2829-2836.
29. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
30. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. Cancer Genome Atlas Research Network.
31. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012, 22:2109-2119.
32. Ciuleanu T, Stelmakh L, Cicenas S, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012, 13:300-308.
33. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012, 18:375-377.
34. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
35. Gadgeel SM Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 2012, 13:96-106.
36. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013, 14:981-988.